Use access key #2 to skip to page content.
$14.24 0.53 (3.87%)
7/3/2008 1:00 PM

ISIS Pharmaceuticals, Inc. (ISIS)

CAPS Rating:
***

The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating ISIS

Add Stock to Watchlist

What the Community Thinks Add a widget featuring this stock to your blog!

Total Players

426 Outperforms
28 Underperforms
 

All-Stars

114 Outperforms
12 Underperforms
 

Wall Street

9 Outperforms
1 Underperforms
 

Players bullish on ISIS are also bullish on:

Players bearish on ISIS are also bearish on:

Ticker Tags

Drug Manufacturers - Other (105), Rule Breakers Universe (161), Small Cap (1922), Biotechnology (293)
Suggest a tag

ISIS Pharmaceuticals, Inc. At A Glance

Current Price: $14.24
Last Trade Time: 7/3/2008 1:00 PM
Open: $0.00
Previous Close: $13.71
Daily Range: $13.61 - $14.25
52-Week Range: $9.52 - $20.15
Volume: 1,044,267
Market Cap: $1.31B
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

ISIS VS S&P 500 (SPY)

ISIS 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for ISIS

More Headlines...

Top Bull Pitch

Recs

7

ISIS Pharmaceuticals, Inc. (ISIS)

Avatar SaintCroix (79.85) Submitted: 11/26/07 10:39 AM

I'm re-upping on this, my favorite biotech. Isis is the antisense pure-play. Read this article to see why I'm excited about antisense:





http://www.signalsmag.com/signalsmag.nsf/CA8B17DF522401B7882...




More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

4

ISIS Pharmaceuticals, Inc. (ISIS)

Avatar mansloth (95.16) Submitted: 8/21/06 1:23 AM

I've looked at this company a couple of times and always get a bad feeling. I've never shorted any business before, but you gotta start somewhere. I'll start with ISIS because:

their technology is antiquated

they are basically a one-trick pony

I don't think their pipeline is very impressive.

I...More

Replies: 4 | Reply | Permalink

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 95 :   1 2 3 4 5 Next » Jump to page:

Show Pitch Replies

Recs

0

 (ISIS)

Avatar tthwebster (< 20) Submitted: 6/28/08 12:07 PM : Outperform Start Price: $13.82 ISIS Score: 4.31

You call it then...


http://seekingalpha.com/article/82981-isis-pharmaceuticals-o...


Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ISIS)

Avatar ToaoMike (62.04) Submitted: 6/18/08 10:17 PM : Outperform Start Price: $14.33 ISIS Score: 5.20

Revolutionary approach to medical drug formulation.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ISIS)

Avatar spacerumsfield (43.71) Submitted: 6/15/08 12:08 PM : Outperform Start Price: $14.85 ISIS Score: 3.22

-Best "anti-sense" pharmaceutical company in the business, having produced the only FDA-approved antisense drug to date.

-Is currently developing 18 different drugs.

-Next product, which has already successfully gone through preclinical studies, will help treat Diabetes, the most epidemic disease in the world. There is a huge potential for profit here.

Report this Post Replies: 1 | Reply | Permalink

Recs

0

 (ISIS)

Avatar JeremyBear (87.53) Submitted: 6/06/08 12:14 PM : Outperform Start Price: $14.96 ISIS Score: 3.85

Large drug coming through which would make them profitable in next 2 years. It is in stage 3 and it is a cholesterol drug which historically have an extremely high likelihood of getting approved once they have gotten to the final stage. DNA is partnering with them and ABT is investing in them. They are the real deal.

The TIGER Biosensor equipment and an extensive pipeline of over fifteen new drugs make this a huge potential LT winner. Best time to own a biotech is right before they become profitable. Get long and stay there.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ISIS)

Avatar bcns (< 20) Submitted: 5/29/08 8:36 AM : Outperform Start Price: $13.57 ISIS Score: 14.09

ISIS has a boat load of patents and is a leader in iRNA which shows great promise. Big pharma needs the ISIS pipeline. ISIS will be acquired within the next year.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 95 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 10 of 10  

picks per page. CHANGE Expand All Pitches

Top
Pick
Player NamePlayer RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackWachovia 77.23 10/11/07 Outperform NS $16.02-11.11%-19.51%+8.40
TrackJefferies 88.02 07/19/07 Outperform NS $11.33+25.68%-18.61%+44.30
TrackNeedham < 20 07/09/07 Outperform NS $10.60+34.34%-17.53%+51.87
TrackTobinSmith < 20 06/22/07 Outperform 1Y $9.53+49.42%-16.12%+65.55
TrackZacks 90.39 06/07/07 Outperform 3M $9.16+55.46%-15.29%+70.74 Toggle the visibility of 60-Second Pitch and replies
TrackFortisBank 98.77 03/20/07 Outperform NS $8.93+59.46%-10.01%+69.47
TrackLehmanBros 88.34 01/29/07 Outperform NS $11.06+28.75%-11.17%+39.92
TrackAGEdwards 94.66 11/10/06 Outperform NS $10.37+37.32%-8.57%+45.88
TrackCowenandCo 76.03 11/09/06 Outperform NS $10.19+39.74%-9.15%+48.89
TrackJimCramer 83.36 03/24/06 Underperform 3W $8.91+59.82%-2.93%-62.75

Results 1 - 10 of 10  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners